title: Bisphosphonates and the dental patient: Part 2.
abstract: With the increased popularity of bisphosphonate therapy for a variety of medical conditions, it is likely, even inevitable, that all dental practitioners will encounter patients on these medications. The purpose of this article is to acquaint the reader with possible treatment options for patients on bisphosphonate therapy, both oral and intravenous. This article will build on the reader's knowledge obtained from part 1, which was published in the August 2007 issue of the Compendium.
authors: Michael
authors: M
authors: Zak
authors: Anthony M
authors: AM
authors: Spina
authors: Russell P
authors: RP
authors: Spinazze
authors: William L
authors: WL
authors: Perkinson
authors: Dennis J
authors: DJ
authors: Spinazze
mesh_terms: D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D010020:Osteonecrosis / Q000097:blood / Q000139:chemically induced* / Q000628:therapy; D010166:Palliative Care; D010455:Peptides / Q000097:blood
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide